Cross-Sector entity
Biogen is the most frequent co-covered peer, appearing in 3 of the 6 tracked stories. Across a 166-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 3. pharma accounts for 3 of the 6 tracked stories, while 1 other category carries the remainder.
6 verified stories tracked
Last mentioned: Aug 3, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 16 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Biogen is the most frequent co-covered peer, appearing in 3 of the 6 tracked stories. Across a 166-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 3. pharma accounts for 3 of the 6 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average. Negative sentiment appears in 17% of the tracked stories. This profile follows 6 Cross-Sector stories mentioning European Medicines Agency (EMA) across the period from February 19, 2026 to August 3, 2026.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering European Medicines Agency (EMA). Shared-story counts are live from our verified record — not editorial picks.
High Court grants permission for judicial review
Judge Cian Ferriter allows Emily Felix's challenge against the HSE and Minister for Health to proceed, citing arguable grounds regarding the delay.
NCPE pharmacoeconomic evaluation completed
The National Centre for Pharmacoeconomics delivers its assessment of Skyclarys' cost-effectiveness to the HSE.
HSE reimbursement application filed
Biogen submits a formal pricing and reimbursement application to the HSE to add Skyclarys to the public drug list.
European market authorisation
The European Commission grants centralised marketing authorisation for Biogen's Skyclarys (omaveloxolone) for patients over 16.
Diagnosis with Friedreich's ataxia
Emily Felix, then 12 years old, is diagnosed with the rare, progressive neuromuscular disease.
Biogen’s orphan drug for Friedreich’s ataxia, approved by the EMA since February 2024, remains mired in Irish reimbursement ambiguity, prompting a patient’s judicial review and highlighting the EU’s fragmented market access for novel therapies.
Emily Felix, 28, launches judicial review against the HSE for failing to decide on funding for Biogen's Friedreich's ataxia drug for nearly two years, despite EMA approval and availability across a dozen EU nations.
A woman with Friedreich’s ataxia sues the HSE over an unacceptably prolonged reimbursement decision for omaveloxolone, a treatment that could slow her decline and that is already standard care in 12 other European countries.
Source: roscommonherald.ie · laois-nationalist.ie
WuXi Biologics' Suzhou facility earned its fourth EMA GMP certificate with zero findings, paving the way for 19 biologic therapies to reach European patients. This achievement reinforces the critical role of rigorous biosafety testing in safeguarding the global healthcare supply chain.
With zero critical findings on its fourth EMA GMP certification, WuXi Biologics now empowers 13 biotech clients to commercialize 19 biologics in Europe. This milestone validates the company's integrated CRDMO model and deepens its competitive moat in the biologics CDMO space.
Source: prnewswire.com · pannaphat.me
A landmark study reveals that the excruciating tropical disease Chikungunya is now capable of local transmission across most of Europe. Driven by the northward migration of the Aedes albopictus mosquito, this shift creates an urgent demand for vaccines and diagnostic infrastructure in previously unaffected regions.
Source: theguardian.com · aol.co.uk
